Press release
Relapsed/Refractory Acute Myeloid Leukemia Clinical Trials, Treatment Drugs, Pipeline Insights and Companies 2024
Relapsed/Refractory Acute Myeloid Leukemia Pipeline
Explore our latest breakthroughs in Relapsed/Refractory Acute Myeloid Leukemia Research. Learn more about our innovative pipeline today! @ Relapsed/Refractory Acute Myeloid Leukemia Pipeline Outlook- https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Relapsed/Refractory Acute Myeloid Leukemia Pipeline Report
• June 2024:- Ryvu Therapeutics SA- A Multicenter, Open-Label, Dose-Finding Clinical Trial to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of RVU120 in Combination With Venetoclax in Participants With Acute Myeloid Leukemia Who Failed Prior Therapy With Ventoclax and a Hypomethylating Agent.
• June 2024:- LLS PedAL Initiative LLC- A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin [GO]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse who are unable to receive additional anthracyclines, or in 2nd relapse.
• DelveInsight's Relapsed/Refractory Acute Myeloid Leukemia pipeline report depicts a robust space with 50+ active players working to develop 75+ pipeline therapies for Relapsed/Refractory Acute Myeloid Leukemia treatment.
• The leading Relapsed/Refractory Acute Myeloid Leukemia Companies such as Ascentage Pharma, Cullinan Oncology, Kronos Bio, Maxinovel Pharmaceuticals, AB Science, CicloMed, Karyopharm Therapeutics, Antengene Corporation, GlycoMimetics, Servier, Novartis, ImmunoGen, and others.
• Promising Relapsed/Refractory Acute Myeloid Leukemia Therapies such as UCART 123, FHD-286, AB8939, ONC201, Sarclisa, TCB008, Keytruda, Uproleselan, Crenolanib, and others.
Stay informed about the cutting-edge advancements in Relapsed/Refractory Acute Myeloid Leukemia Treatments. Download for updates and be a part of the revolution in oncology care @ Relapsed/Refractory Acute Myeloid Leukemia Clinical Trials Assessment- https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Relapsed/Refractory Acute Myeloid Leukemia Emerging Drugs Profile
• APG-2575: Ascentage Pharma
APG-2575 is a novel oral Bcl-2 selective small molecule inhibitor under development by Ascentage Pharma. It restores the programmed cell death mechanism (apoptosis) of tumor cells by selectively inhibiting Bcl-2 protein, thereby inducing tumor cell apoptosis. , to achieve the purpose of tumor treatment. APG-2575 is the first locally developed Bcl-2 selective inhibitor to enter clinical stage in China. APG-2575 has been granted orphan drug designation by the US FDA for five indications (Indications: refractory chronic lymphocytic leukemia CLL, multiple myeloma, Waldenström macroglobulinemia, acute myeloid leukemia, follicular lymphoma).
• CLN 049: Cullinan Oncology
CLN-049 (Florentine) is a humanized bispecific T cell engaging antibody being developed for the treatment of acute myeloid leukemia (AML). CLN-049 is designed to simultaneously bind to FLT3 on targeted leukemic cells and to CD3 on T cells, triggering the T cells to kill the selected cancer cells via their intrinsic cytolytic mechanisms. FLT3 is expressed frequently on AML cells and leukemic blasts but minimally on healthy blood cells, unlike other tumor surface antigens identified in AML, such as CD33 and CD123. CLN-049 can mediate potent and specific lysis of AML cells in vitro and promotes enhanced survival of mice bearing AML tumors. A phase I clinical trial with CLN-049 is currently ongoing for the treatment of patients with relapsed/refractory AML or MDS.
• Lanraplenib: Kronos Bio
Lanraplenib, is a next-generation SYK inhibitor that has previously been studied as a potential treatment for autoimmune diseases. In preclinical studies, Lanraplenib was shown to have anti-leukemic activity against NPM1-mutated and FLT3-mutated AML samples. Lanraplenib, is being developed for the treatment of patients with relapsed/refractory FLT3-mutated AML and patients newly diagnosed with NPM1-mutated and/orFLT3-mutated AML who are older than 75 years old or are not eligible for intensive induction chemotherapy.
Learn more about Relapsed/Refractory Acute Myeloid Leukemia Drugs opportunities in our groundbreaking Relapsed/Refractory Acute Myeloid Leukemia Research and development projects @ Relapsed/Refractory Acute Myeloid Leukemia Unmet Needs- https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Relapsed/refractory acute myeloid leukemia (AML) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Relapsed/Refractory Acute Myeloid Leukemia Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule
Discover the latest advancements in Relapsed/Refractory Acute Myeloid Leukemia Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Relapsed/Refractory Acute Myeloid Leukemia Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Relapsed/Refractory Acute Myeloid Leukemia Market Drivers
• Rising incidence of Acute Myeloid Leukemia, advancements in pharmacology and molecular biology to promote drug development, rising geriatric population are some of the important factors that are fueling the Relapsed/Refractory Acute Myeloid Leukemia Market.
Relapsed/Refractory Acute Myeloid Leukemia Market Barriers
• However, high cost associated with the management of AML, side effects associated with the AML treatment and other factors are creating obstacles in the Relapsed/Refractory Acute Myeloid Leukemia Market growth.
Scope of the Relapsed/Refractory Acute Myeloid Leukemia Pipeline Report
• Coverage- Global
• Relapsed/Refractory Acute Myeloid Leukemia Companies- Ascentage Pharma, Cullinan Oncology, Kronos Bio, Maxinovel Pharmaceuticals, AB Science, CicloMed, Karyopharm Therapeutics, Antengene Corporation, GlycoMimetics, Servier, Novartis, ImmunoGen, and others.
• Relapsed/Refractory Acute Myeloid Leukemia Therapies- UCART 123, FHD-286, AB8939, ONC201, Sarclisa, TCB008, Keytruda, Uproleselan, Crenolanib, and others.
• Relapsed/Refractory Acute Myeloid Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Relapsed/Refractory Acute Myeloid Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Relapsed/Refractory Acute Myeloid Leukemia Pipeline on our website @ Relapsed/Refractory Acute Myeloid Leukemia Drugs and Companies- https://www.delveinsight.com/sample-request/relapsed-refractory-acute-myeloid-leukemia-r-r-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Relapsed/refractory acute myeloid leukemia (AML): Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Relapsed/refractory acute myeloid leukemia (AML)- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name : Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase I/II)
11. APG-2575: Ascentage Pharma
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. CLN 049: Cullinan Oncology
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name : Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Relapsed/refractory acute myeloid leukemia (AML) Key Companies
21. Relapsed/refractory acute myeloid leukemia (AML) Key Products
22. Relapsed/refractory acute myeloid leukemia (AML)- Unmet Needs
23. Relapsed/refractory acute myeloid leukemia (AML)- Market Drivers and Barriers
24. Relapsed/refractory acute myeloid leukemia (AML)- Future Perspectives and Conclusion
25. Relapsed/refractory acute myeloid leukemia (AML) Analyst Views
26. Relapsed/refractory acute myeloid leukemia (AML) Key Companies
27. Appendix
List of Top Selling Market Research Report in 2024
Brucellosis Market- https://www.delveinsight.com/report-store/brucellosis-market
Pacemakers Market- https://www.delveinsight.com/report-store/pacemakers-market
Surgical Energy Instruments Market- https://www.delveinsight.com/report-store/surgical-energy-generators-market
Intraocular Lymphoma Market- https://www.delveinsight.com/report-store/intraocular-lymphoma-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Ventral Hernia Market- https://www.delveinsight.com/report-store/ventral-hernia-market
Novel Drug Delivery Devices Market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Skin Neoplasms Market- https://www.delveinsight.com/report-store/skin-neoplasms-market
Hip Replacement Devices Market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Varicose Vein Treatment Devices Market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
Bone Growth Stimulators Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Sepsis Market- https://www.delveinsight.com/report-store/sepsis-market
Transcatheter Heart Valve Replacement Devices Market- https://www.delveinsight.com/report-store/transcatheter-heart-valve-replacement-devices-market
Endoscopic Ultrasound Market- https://www.delveinsight.com/report-store/endoscopic-ultrasound-market
Cardiac Monitoring Devices Market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
Trichomoniasis Market- https://www.delveinsight.com/report-store/trichomoniasis-market-insights
Radiodermatitis Market- https://www.delveinsight.com/report-store/radiodermatitis-market
HDAC Inhibitors Market- https://www.delveinsight.com/report-store/hdac-inhibitors-market
CXCR Inhibitors Market- https://www.delveinsight.com/report-store/c-x-c-chemokine-receptor-inhibitors-competitive-landscape-market-and-pipeline-analysis
Lactose Intolerance Market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Total Knee Arthroplasty Market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Microscopy Device Market- https://www.delveinsight.com/report-store/microscopy-device-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Pigment Epithelial Detachment Market- https://www.delveinsight.com/report-store/pigment-epithelial-detachment-market
Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market
UK Healthcare Report- https://www.delveinsight.com/report-store/uk-healthcare-outlook-report
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Relapsed/Refractory Acute Myeloid Leukemia Clinical Trials, Treatment Drugs, Pipeline Insights and Companies 2024 here
News-ID: 3663354 • Views: …
More Releases from DelveInsight Business Research LLP
Postoperative acute pain Market Size is Set for Rapid Growth as Innovative Treat …
The market size of Postoperative acute pain is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Taiwan Liposome Company (TLC)., Teikoku Pharma, Concentric Analgesics, Arthritis Innovation Corporation, MedinCell, Surface Ophthalmics, Salvat Laboratories, Vertex Pharmaceuticals, Formosa Pharmaceuticals, Avenue Therapeutics, Cali Pharmaceuticals LLC
[Nevada, United States] - DelveInsight's "Postoperative acute pain Market Insights, Epidemiology, and Market Forecast 2034."…
Oligometastatic Disease Market Size is Set for Rapid Growth as Innovative Treatm …
The Oligometastatic Disease market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as ImmuneSensor Therapeutics, POINT Biopharma, Novartis Pharmaceuticals, AstraZeneca PLC, Bristol-Myers Squibb Company
[Nevada, United States] - DelveInsight's "Oligometastatic Disease Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Oligometastatic Disease, covering historical and predicted epidemiology, market trends, and treatment…
PD-1 Non-Small Cell Lung Cancer Market Size is Set for Rapid Growth as Innovativ …
The PD-1 Non-Small Cell Lung Cancer market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Regeneron Pharmaceuticals, Sanofi, Bavarian Nordic,, Chengdu MedGenCell Co. Ltd., Merck Sharp & Dohme LLC, Dynavax Technologies Corporation, BeiGene, Tesaro Inc., Bristol-Myers Squibb
[Nevada, United States] - DelveInsight's "PD-1 Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast 2034."…
Bone metastasis in Solid Tumor Market Size is Set for Rapid Growth as Innovative …
The Bone metastasis in Solid Tumor market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Mabwell (Shanghai) Bioscience Co. Ltd., Novartis, Institut Bergonié ,Pfizer, GlaxoSmithKline, Amgen, QSAM Therapeutics Inc., Actuate Therapeutics Inc., Hoffmann-La Roche
[Nevada, United States] - DelveInsight's "Bone metastasis in Solid Tumor Market Insights, Epidemiology, and Market Forecast 2034." report offers a…
More Releases for Acute
Acute Conjunctivitis Treatment Market: The Future Insights Of Global Acute Conju …
Acute Conjunctivitis Treatment Market
Acute Conjunctivitis Treatment Market, or pink eye, is an irritation or inflammation of the conjunctiva that covers the white part of the eyeball. It can be caused by allergies or a bacterial or viral infection. Acute Conjunctivitis Treatment Market can be highly communicable and can be spread easily by the contact with secretions of eye from the infected person. Conjunctivitis often resolves on its own, but…
Pipeline Review, H2 2017 of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic …
"Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2017" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect.
. .
Description-
' …
Acute Renal Failure (ARF) (Acute Kidney Injury) Market: Industry Size, Share, Gr …
Latest industry research report on: Acute Renal Failure (ARF) (Acute Kidney Injury) Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2017, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline landscape.
Request For Sample Report…
Acute Renal Failure (ARF) (Acute Kidney Injury) Pipeline Review, H2
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2017” to its report offerings. The report covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1230595
Acute kidney failure occurs when kidneys suddenly become unable to filter waste products from blood.…
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical T …
ReportsWorldwide has announced the addition of a new report title Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports.
GlobalData's clinical trial report, “Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trials scenario. This report provides top line data relating to…
H2 2016 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeut …
Albany, New York, January 03, 2017: A recent forecast report focusing on the Acute Myelocytic Leukemia Market has been added to the wide portfolio of Market Research Hub (MRH). It is entitled as, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2016” which has been equipped by in-depth market examination with inputs from the industry experts. It covers the current market scenario and also its future growth…
